3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
63
Colonic Neoplasms
29
Rectal Neoplasms
25
Neoplasm Metastasis
11
Stomach Neoplasms
8
Carcinoma, Hepatocellular
7
Pancreatic Neoplasms
6
Neoplasms
6
Esophageal Neoplasms
4
Adenocarcinoma Of Esophagus
4
Liver Neoplasms
3
Ovarian Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Recurrence
1
Prostatic Neoplasms
1
Postoperative Complications
1
Peritoneal Neoplasms
1
Operable T2-3N+M0 Rectal Cancer (Stage III)
1
Neuropathy, Painful
1
Neuralgia
1
Neoplasm Recurrence, Local
1
Melanoma
1
Malignant Solid Tumour
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Gastrointestinal Neoplasms
1
Cold Hypersensitivity
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Basal Cell
1
Interventions
Trastuzumab
351
Paclitaxel
334
Cyclophosphamide
315
Docetaxel
292
Capecitabine
181
Doxorubicin
180
Letrozole
165
Tamoxifen
145
Bevacizumab
124
Fulvestrant
118
Carboplatin
118
exemestane
111
Lapatinib
111
Anastrozole
111
Radiotherapy
105
Epirubicin
104
Gemcitabine
97
palbociclib
83
Exercise
78
Vinorelbine
77
Fluorouracil
77
Surveys and Questionnaires
71
pertuzumab
68
Filgrastim
64
Albumin-Bound Paclitaxel
64
Magnetic Resonance Spectroscopy
56
eribulin
55
Everolimus
52
Blood Specimen Collection
51
Zoledronic Acid
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Neoplasms
×
Folfox protocol
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled